Table 3

Quality of the thyroid nodule/cancer clinical practice guidelines for the six domains of the AGREE-II Instrument (D1 to D6) and the overall impression of the four assessors
Domain AACE/AME/ETA (2010) ATA (2009) BTA (2007) ESMO (2012) GAES (2013) IKNL (2007) LATS (2009) NCCN (2013) NCN (2000) SEOM (2011)
D1
1 6 (0) 6.25 (0.5) 6.5 (0.58) 3.5 (0.58) 5 (0.82) 6.5 (0.58) 6 (0) 6.25 (0.5) 6 (0) 3.5 (0.58)
2 5.75 (0.5) 6.5 (0.58) 6.25 (0.96) 3.25 (0.96) 5 (0.50) 6.5 (0.58) 6 (0) 5.5 (0.58) 4.25 (0.5) 3.5 (0.58)
3 6 (0.82) 5.5 (1.29) 6 (1.41) 2.25 (1.26) 4.25 (0.96) 5.75 (1.5) 5.25 (0.96) 5.5 (1.29) 5 (0.82) 3.25 (0.5)
D2
4 5.5 (0.58) 6.25 (0.5) 6.25 (0.5) 2.5 (1.29) 5 (1.15) 7 (0) 4 (1.41) 6.75 (0.5) 5.25 (0.5) 2.75 (0.5)
5 3.25 (0.96) 3.75 (1.71) 4.25 (1.71) 1.75 (0.50) 2.75 (0.96) 3 (1.41) 1.75 (0.50) 2.5 (0.58) 1.75 (0.5) 2 (0)
6 6 (0) 6 (0.82) 6.25 (0.5) 2.75 (0.50) 5 (0) 6.5 (0.58) 5.25 (0.50) 6.25 (0.5) 5.25 (0.96) 3 (0.82)
D3
7 6 (0.82) 3.75 (0.96) 4.5 (1.29) 1.25 (0.50) 5 (0.82) 6.75 (0.50) 3.75 (0.96) 3.5 (0.58) 2.75 (0.50) 1.75 (0.50)
8 4 (0.82) 5.5 (1.29) 4 (0.82) 1 (0) 5.25 (0.50) 6.75 (0.50) 3 (0.82) 4.25 (0.50) 3.25 (0.50) 1.25 (0.50)
9 4.5 (1.73) 4 (1.15) 4.75 (1.50) 1.5 (0.58) 3.5 (1.29) 6.25 (0.50) 3 (0.82) 4.5 (1.29) 3.25 (0.50) 1.75 (0.50)
10 5.25 (0.96) 4.75 (0.5) 5 (1.41) 3 (0) 5.75 (0.50) 6.5 (0.58) 4.25 (1.50) 5 (0.82) 3.75 (1.50) 2 (0)
11 4.25 (1.50) 4.25 (0.96) 4.5 (1.29) 2.75 (0.96) 4.5 (0.58) 6.25 (0.50) 3.75 (1.50) 5.75 (0.50) 3.25 (1.26) 2.25 (0.50)
12 6 (0) 5.25 (1.71) 6.25 (0.96) 4.75 (0.50) 4.5 (1.00) 6.5 (0.58) 2.75 (0.50) 4 (0.82) 2.5 (1.00) 2.75 (0.96)
13 4 (1.15) 5.5 (0.58) 5.75 (0.50) 2 (0) 4 (1.41) 5.75 (0.50) 5.25 (0.50) 4 (1.15) 4.5 (1.29) 2 (0)
14 4 (1.83) 4.75 (0.96) 5 (0.82) 2 (0) 3.75 (0.50) 5.75 (0.50) 4.25 (1.50) 5 (1.41) 2.25 (0.50) 2 (0)
D4
15 6 (0.82) 6 (0) 6 (0) 3.75 (0.96) 5 (0) 6.25 (0.50) 4.5 (0.58) 6.25 (0.50) 4.5 (0.58) 4 (0)
16 5 (1.83) 3.75 (0.96) 3.75 (0.96) 3 (0.82) 3.75 (0.96) 4.5 (1.73) 3.75 (1.50) 5.5 (0.58) 4 (1.15) 3.25 (0.96)
17 6 (0.82) 6 (0) 5.75 (0.50) 3.75 (0.50) 6 (0) 6.25 (0.50) 4.5 (0.58) 6 (0) 4.75 (0.50) 4 (0)
D5
18 3 (0.82) 3.25 (0.50) 4.5 (0.58) 2 (0) 2.75 (1.26) 5.25 (0.50) 3 (0) 4 (0.82) 2.75 (0.50) 2 (0)
19 4.25 (1.50) 4 (1.41) 6 (0.82) 2.75 (0.96) 4.25 (1.50) 6 (0) 4.25 (1.50) 5.75 (0.50) 3.5 (1.29) 3 (1.15)
20 3.25 (1.71) 3.75 (1.26) 3.25 (1.26) 2 (0) 3 (1.41) 4.25 (1.26) 3.5 (1.29) 4 (0.82) 2.25 (0.50) 2.25 (0.50)
21 2.75 (0.96) 3.25 (1.50) 3.75 (1.71) 2.75 (1.50) 2.5 (1.00) 3.75 (0.96) 3 (1.15) 4 (0.82) 2.5 (1.00) 2 (0)
D6
22 5 (1.15) 6 (0.82) 5.5 (1.73) 3 (0.82) 5.25 (0.96) 6 (0) 4 (1.41) 5.75 (0.50) 1.75 (0.50) 4.5 (1.29)
23 6.5 (0.58) 5.75 (1.89) 5.5 (1.73) 3.75 (0.96) 2.25 (0.50) 5.5 (1.29) 4.25 (1.50) 6.5 (0.58) 3.75 (0.96) 1.5 (0.58)
Overall 5.75 (0.50) 6 (0) 6.25 (0.50) 3.75 (0.96) 5 (0) 6.25 (0.50) 4.25 (0.50) 5.5 (0.58) 4.25 (0.96) 3 (0)

Domain areas are as follows: D1, scope and purpose; D2, stakeholder involvement; D3, rigor of involvement; D4, clarity of presentation; D5, applicability; D6, editorial independence. All the 23 items of the Appraisal of Guidelines Research and Evaluation II (AGREE-II) instrument are rated on a seven-point scale from 7 (strongly agree) down to 1 (strongly disagree). Overall: the numbers in the overall row represent the averages of the scoring performed by four assessors. Guideline group abbreviations are as follows: AACE/AME/ETA American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi and European Thyroid Association, ATA American Thyroid Association, BTA British Thyroid Association and Royal College of Physicians, ESMO European Society for Medical Oncology, GAES German Association of Endocrine Surgeons, IKNL Dutch Endocrine Society and Dutch Society of Nuclear Medicine, LATS Latin American Thyroid Society, NCCN National Comprehensive Cancer Network, NCN Northern Cancer Network and SEOM Spanish Society of Medical Oncology.

Huang et al.

Huang et al. BMC Medicine 2013 11:191   doi:10.1186/1741-7015-11-191

Open Data